Announced details
Overactive bladder (OAB) treatment
Kyorin Pharmaceutical granted Sumitomo Pharma exclusive development, manufacturing and sales rights for vibegron in certain parts of Asia in 2023. The rights were subsequently transferred to Marubeni Pharmaceuticals Co., Ltd.
Marubeni Pharmaceuticals Co., Ltd. is located in Chuo-ku, Tokyo, and its president and representative director is Nishinaka Shigeyuki (西中 重行). Established in 2025, it engages in pharmaceutical sales in China and Southeast Asia. Taiwan Marubeni Pharmaceutical Co., Ltd. is a subsidiary of Marubeni Pharmaceuticals Co., Ltd. and sells prescription pharmaceuticals in Taiwan and provides and collects product information for healthcare professionals.
Taiwan
The impact on the consolidated earnings forecast for the fiscal year ending March 2027 is expected to be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Vibegron, Gemtesa |
| Counterparty | Taiwan Marubeni Pharmaceutical Co., Ltd., Marubeni Pharmaceuticals Co., Ltd. |
| Counterparty overview | Marubeni Pharmaceuticals Co., Ltd. is located in Chuo-ku, Tokyo, and its president and representative director is Nishinaka Shigeyuki (西中 重行). Established in 2025, it engages in pharmaceutical sales in China and Southeast Asia. Taiwan Marubeni Pharmaceutical Co., Ltd. is a subsidiary of Marubeni Pharmaceuticals Co., Ltd. and sells prescription pharmaceuticals in Taiwan and provides and collects product information for healthcare professionals. |
| Relationship with the Company | Kyorin Pharmaceutical granted Sumitomo Pharma exclusive development, manufacturing and sales rights for vibegron in certain parts of Asia in 2023. The rights were subsequently transferred to Marubeni Pharmaceuticals Co., Ltd. |
| Launch date | 22 September 2026 (actual) |
| Applicable area | Overactive bladder (OAB) treatment |
| Location | Taiwan |
| Impact on Business Performance | The impact on the consolidated earnings forecast for the fiscal year ending March 2027 is expected to be minor. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To promote the adoption of this product in the contracted countries across Asia through collaboration with Marubeni Pharmaceuticals Co., Ltd. and contribute to people's health.